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Abstract  1 
Purpose: To determine whether decreasing illumination of the Pelli-Robson contrast 2 
sensitivity (CS) chart and MP-1 microperimeter to low mesopic conditions is more sensitive 3 
to vision changes occurring with healthy ageing and in early and intermediate age-related 4 
macular degeneration (AMD) and whether these mesopic tests can differentiate visual 5 
function between healthy older participants with and without AMD risk genotypes. 6 
Methods: Retinal sensitivity was measured in 98 healthy participants (19-85 years) and 21 7 
AMD (AREDS Grade 2/3) patients (73.9±6.5 years) using the Pelli-Robson CS chart and MP-8 
1 microperimeter under low mesopic and standard illumination. The effect of ageing and 9 
AMD on retinal sensitivity was estimated using regression analysis. Healthy older participants 10 
(>50 years; n=24) were genotyped for AMD risk genes CFH and/or ARMS2 and retinal 11 
sensitivity was compared between genotypes.  12 
Results: With healthy ageing, photopic and mesopic Pelli-Robson CS showed a similar 13 
decline (-0.004 log CS/year). In AMD, photopic CS showed a similar decline to healthy 14 
ageing (-0.004 log CS/year) while mesopic CS was significantly reduced (-0.007 log 15 
CS/year). Both standard and low mesopic microperimetry showed a significant decline (-0.51 16 
and -0.73 % contrast/year) with healthy ageing and greater decline (-0.73 and -0.99 % 17 
contrast/year) with AMD onset. Pelli-Robson CS and microperimetry sensitivity did not differ 18 
between AMD risk genotypes.  19 
Conclusions: Mesopic Pelli-Robson CS detects functional deficits before photopic CS in early 20 
and intermediate AMD that can be differentiated from normal ageing. This test can be easily 21 
administered in clinical practice and may provide a means for early detection of retinal 22 
dysfunction.  23 
Key words: mesopic, contrast sensitivity, microperimetry, macular degeneration24 
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Introduction 25 
Age-related macular degeneration (AMD) is a progressive condition affecting central vision 26 
and a leading cause of blindness in older adults worldwide (Friedman et al. 2004; Klein et al. 27 
1992; Mitchell et al. 1995). Despite intensive research, its pathogenesis is still unclear but 28 
AMD has been described as a disease exhibiting the characteristics of accelerated ageing 29 
(Ardeljan & Chan 2013). There is currently no cure for AMD and attention has turned 30 
towards early detection of macular changes to facilitate lifestyle and dietary modifications 31 
that may slow or even halt disease progression (Mares et al. 2011).  32 
There has been significant focus on understanding cone (photopic) and rod (scotopic) 33 
mediated visual function with both showing a reduction with age and in early AMD (Cheng & 34 
Vingrys 1993; Feigl et al. 2004, 2005; Hogg & Chakravarthy 2006; Lovie-Kitchin & Feigl 35 
2005; Neelam et al. 2009; Swann & Lovie-Kitchin 1991). Mesopic vision offers great 36 
potential for the development of new tests for the early detection of retinal diseases affecting 37 
both the rods and cones (for review, Zele & Cao 2015). For the early detection of AMD, low 38 
luminance/low contrast and mesopic vision tests of combined rod and cone function have 39 
been recommended (Feigl et al. 2011; Lovie-Kitchin & Feigl 2005). Indeed, mesopic critical 40 
fusion frequency (CFF) is lower in healthy persons with no retinal disease but who have high 41 
risk AMD genotypes when compared to healthy persons with low risk genotypes (Feigl et al. 42 
2011). Nevertheless, high contrast visual acuity (VA) and contrast sensitivity (CS) tests are 43 
still the most common measures of macular function in a clinical practice. While mesopic 44 
vision testing shows higher sensitivity to vision loss than photopic testing, most scotopic and 45 
mesopic psychophysical and electrophysiological tests have not made their entrance into 46 
clinical practice. 	47 
In this study we investigated two clinical tests that assess central retinal function; the Pelli-48 
Robson contrast sensitivity chart (Pelli et al. 1988) and MP-1 microperimetry, a newer 49 
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technology which shows promise in the localized functional documentation of vision in AMD 50 
(Dinc et al. 2007; Meleth et al. 2011; Midena et al. 2007; Parravano et al. 2009; Pilotto et al. 51 
2013; Rohrschneider et al. 2008; Tarita-Nistor et al. 2008; Wu et al. 2014). Our aim was to 52 
determine whether modification of these clinical tests to measure vision under low mesopic 53 
illumination is more sensitive to changes in retinal function due to normal ageing and early or 54 
intermediate AMD compared to the standard protocols, hence may be used for early detection 55 
of the disease. In a pilot study, we aimed to determine whether retinal sensitivity measured 56 
under mesopic illumination differed in healthy older participants with and without the AMD 57 
(CFH and ARMS2) risk genotypes. 58 
 59 
Materials and methods 60 
Participants 61 
One hundred and nineteen participants (58 male, 61 female) between the ages of 19 and 85 62 
years were recruited from volunteers at Queensland University of Technology (QUT) and the 63 
QUT Eye clinic. Ninety-eight participants (47M and 51F; age range 19 – 85 years) had no 64 
ocular disease and served as the healthy ageing group. Of these 98 healthy participants, 15 65 
participants (7M and 8F; age 69.0 ± 5.6 years) comprised the age-matched control group to 66 
the 21 participants (11M and 10F; age 73.9 ± 6.5 years) with AMD in both eyes (AREDS 67 
grade 2 or 3) based on the results of two independent gradings of the fundus photographs 68 
(Age-Related Eye Disease Study Research Group 2001). Where AMD was present in both 69 
eyes, the patients’ preferred eye was measured. Where participants had AREDS Grade 1 in 70 
one eye, the eye with AMD was chosen as the study eye. The number of AMD patients with 71 
the study eye for each grade is given in Table 1. Power analysis determined a required sample 72 
size of 10 participants (5 per group) to statistically detect a significant mean difference of 0.4 73 
log contrast between mesopic and photopic contrast sensitivity with a power of 95%. A 74 
sample size of 19 participants per group was required to statistically detect a mean difference 75 
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of 2 dB (1.6 % contrast) between high mesopic and low mesopic microperimetry with a 76 
power of 95%. An interviewer-administered questionnaire determined visual health history, 77 
family history of AMD, medication use, diet and supplements use and AMD risk factors such 78 
as smoking. All participants underwent an ophthalmic examination, which included high 79 
contrast VA (Bailey-Lovie letter chart, NVRI, Australia), colour vision (Lanthony D-15 80 
desaturated, Richmond Products, Albuquerque, NM), tonometry (iCare TA01, Helsinki, 81 
Finland), optical coherence topography (OCT, Cirrus HD-OCT; Carl Zeiss Meditec, USA), 82 
ophthalmoscopy and colour fundus photography (CR-1, Canon, Australia). The healthy 83 
participants had normal vision (6/6 or better), crystalline lens opacities ≤ Grade 2 (LOCS III) 84 
(Chylack et al. 1993), no ocular disease and were in good general health. The AMD patients 85 
had a best corrected VA ≥ 6/9, crystalline lens opacities ≤ Grade 2 (LOCS III) and no history 86 
of ocular or systemic disease other than AMD.  87 
Insert Table 1 approximately here. 88 
As AMD is a multifactorial disease including environmental and genetic risk factors (Seddon 89 
et al. 2009), we genotyped 24 of the healthy older participants aged > 50 years to determine 90 
whether AMD risk genotypes were a contributing factor to a decline in retinal function in 91 
older age. Participants were genotyped by means of saliva samples collected using self-92 
collection kits (Oragene DNA self-collection kit, DNA Genotek Inc, Ottawa, Ontario, 93 
Canada). DNA extraction and genotyping was completed commercially using a restriction 94 
fragment length polymorphism (RFLP) technique and screened for the SNPs of the 95 
complement factor H gene (CFH Y402H; rs1061170) and age-related maculopathy 96 
susceptibility 2 gene (ARMS2; rs10490924) which have both been linked to AMD (Ross et al. 97 
2007). Participants were classified as high, medium or low risk depending on homozygous or 98 
heterozygous risk alleles for one or both SNPs (Rivera et al. 2005).  99 
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Written informed consent was obtained from all participants after full explanation of 100 
procedures and possible risks of the study. The study was conducted in accordance with the 101 
requirements of the Queensland University of Technology Human Research Ethics 102 
Committee and the tenets of the Declaration of Helsinki.  103 
 104 
Visual function testing 105 
Contrast sensitivity was measured using a wall mounted (90 x 60 cm) Pelli-Robson chart 106 
(Mäntyjärvi & Laitinen 2001; Pelli et al. 1988; Puell et al. 2004) with 16 triplets of 4.9 × 4.9 107 
cm letters that subtend 3° at a 1 m viewing distance. These letters are arranged in 8 lines with 108 
two triplets per line. Contrast levels within each triplet are the same and contrast decreases by 109 
a factor of 0.15 log units in each successive triplet, reading from left to right and down the 110 
chart. At the manufacturer recommended 1 m test distance, the letter size corresponds to a 111 
spatial frequency of ~1 c/°. In clinical practice this test is administered under bright ambient 112 
(photopic) room illumination (> 85 lux). Illumination was determined at several locations 113 
within the consultation room using a calibrated ILT1700 photometer (International Light 114 
Technologies, Peabody, MA, USA). For the photopic test condition the mean room 115 
illumination was set at 85 lux; a dimmer switch was used to reduce the room illumination to a 116 
mean level of 1.04 lux for the mesopic test conditions. Binocular performance is better than 117 
monocular in normally sighted people due to summation (Campbell & Green 1965), however, 118 
normal ageing reduces binocular summation (Pardhan 1996; Ross et al. 1985) and we were 119 
interested in this effect in our cohort of participants with and without AMD. Therefore, 120 
participants were tested binocularly under photopic and mesopic conditions using two Pelli-121 
Robson charts with different letters to prevent memorization. Although the AMD eyes had a 122 
similar grading result in each eye (AREDS 2 or 3), the patients were also tested monocularly 123 
to allow for the different stages of disease and the results from the better eye and worse eye 124 
were therefore compared to the monocular results of the age-matched healthy controls.  125 
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Macular sensitivity was measured monocularly using the MP-1 microperimeter (Nidek 126 
Technologies, Japan) (Feigl et al. 2011; Midena et al. 2010; Rohrschneider et al. 2008) under 127 
standard testing conditions and custom modified low mesopic testing conditions following 128 
established protocols (Rohrschneider et al. 2008). The microperimeter operates at (high) 129 
mesopic light levels (1.27 cd.m-2 background) in the upper range of rod sensitivity (CIE 1989) 130 
and therefore visual detection is likely to be cone dominated. We were interested to determine 131 
if a reduction in the luminance to 0.801 cd.m-2 increased the tests’ sensitivity to visual loss by 132 
increasing the level of rod sensitivity relative to cone sensitivity without excluding cone input 133 
as occurs under scotopic microperimetry (Nebbioso et al. 2014). A pilot study (including 0.1, 134 
0.2, 0.3, 0.5 and 1 ND’s) determined that a 0.2 neutral density (ND) filter was optimal to 135 
reduce the background to a low mesopic luminance (0.801 cd.m-2) without affecting the real-136 
time fundus tracking ability of the internal camera. After pupil dilation (tropicamide 1% and 137 
phenylephrine 2.5%), microperimetry was performed in the right eye in healthy participants 138 
and in the eye with better VA in AMD patients. Participants fixated on a central red cross (1°) 139 
and the customized program randomly presented a Goldmann III (0.41° diameter), 200 ms 140 
white stimulus on a 1.27 cd.m-2 background to 40 retinal points within 10° of the fovea. 141 
Retinal sensitivity (decibels) was measured using a 4-2 staircase strategy, increasing from 0 142 
dB (maximum contrast required to see stimulus) in 2 dB increments, to 20 dB (minimum 143 
contrast required to see stimulus). This protocol ensured measurement of the entire macular 144 
region whilst minimising testing time and thereby reducing the effect of fatigue (Convento & 145 
Barbaro 2007).  146 
 147 
Analysis 148 
Statistical analyses were performed using SPSS (version 21; IBM Corporation, Armonk, NY, 149 
USA). Contrast sensitivity was scored under photopic and mesopic illumination as the lowest 150 
contrast level at which at least two of the three letters in a triplet was identified correctly 151 
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(Pelli et al. 1988). Linear regression analysis was performed to determine the effect of ageing 152 
and onset of AMD on contrast sensitivity as measured under different illumination levels. 153 
Microperimetry data were averaged for each participant over the 40 tested retinal points. As 154 
AMD affects paracentral before central areas in early stages of the disease (Cheng & Vingrys 155 
1993; Swann & Lovie-Kitchin 1991), data were also analyzed in three concentric rings at 2°, 156 
6° and 10° eccentricity to determine whether there is a location effect. To allow direct 157 
comparison of the standard microperimetry and low mesopic microperimetry data, the decibel 158 
values were converted to macular sensitivity (%). Linear regression analysis was performed to 159 
determine the effect of ageing and onset of AMD on retinal sensitivity under standard and low 160 
mesopic illumination. To determine the effect of AMD grade on retinal sensitivity and to 161 
account for the age difference between age-matched controls and AMD participants, each 162 
parameter (contrast sensitivity and mean macular sensitivity) was evaluated using 163 
independent t-tests. A p-value of < 0.05 was considered statistically significant. The 164 
diagnostic value of the CS and microperimetry tests measured under mesopic illumination 165 
was evaluated using receiver operator characteristic (ROC) analysis by quantifying the 166 
difference between the AMD patients and age-matched control participants and reported as 167 
area under the curve (AUC). The effect of AMD risk genotypes on retinal sensitivity (CS and 168 
MP-1) in the healthy older participants was investigated and descriptive statistics reported.   169 
 170 
Results 171 
Contrast sensitivity 172 
Binocular Pelli-Robson CS was completed in 73 out of 98 healthy participants (37M and 36F) 173 
(25 participants who completed microperimetry did not return for CS testing) and in 21 early 174 
and intermediate AMD patients (11M and 10F) under photopic and mesopic illumination 175 
(Fig. 1). There was no significant difference between AMD grades for photopic CS (t [19] = 176 
0.83, p = 0.418) or mesopic CS (t [15] = 0.42, p = 0.679), therefore the AMD patients were 177 
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combined to increase the sample power. Within the healthy participants group (Panel A, 178 
Fig.1), there was a significant linear decline in binocular CS with age for both photopic (F1,72 179 
= 29.41, R2 = 0.29, p < 0.0001, slope = -0.004 log CS per year) and mesopic (F1,72 = 23.5, R2 = 180 
0.25, p < 0.0001, slope = -0.004 log CS per year) conditions, consistent with previous 181 
findings (Mäntyjärvi & Laitinen 2001; Puell et al. 2004); the slopes of the photopic and 182 
mesopic data were not significantly different from each other, however CS was lower under 183 
the mesopic illumination condition. On inclusion of the AMD participants (Panel B, Fig. 1), 184 
the slope of the regression line for the mesopic illumination showed a further significant 185 
decline in binocular CS (F1,93 = 70.96, R2 = 0.43, p < 0.0001, slope = -0.007 log CS per year) 186 
whereas it remained unchanged for photopic illumination (F1,93 = 57.23, R2 = 0.38, p < 0.0001, 187 
slope = -0.004 log CS per year), indicating a more pronounced visual deficit under mesopic 188 
testing. Fifteen out of 21 AMD patients (7M and 8F; age 73.9 ± 6.5 years) completed the 189 
monocular CS test and the mean (μ ± SD) CS of each eye (better and worse) of the AMD 190 
group was compared to the mean CS in the dominant eye of 15 age-matched healthy controls 191 
(7M and 8F; age 69.0 ± 5.6 years) (Fig. 2). Under photopic conditions there was no 192 
significant difference between groups for the better eye (t [28] = 1.76, p = 0.09) or worse eye 193 
(t [28] = 0.88, p = 0.39). Under mesopic conditions, the AMD group had significantly lower 194 
sensitivity in both the better eye (t [28] = 3.08, p = 0.005) and worse eye (t [28] = 3.01, p = 195 
0.005). The ROC analysis showed that the AUC for AMD patients was higher with mesopic 196 
CS than photopic CS (mesopic AUC = 0.92; photopic AUC = 0.81) whereas the AUC for 197 
age-matched controls was similar for both mesopic and photopic CS conditions (mesopic 198 
AUC = 0.70; photopic AUC = 0.66). 199 
 200 
Microperimetry 201 
Microperimetry was performed in 89 out of 98 healthy participants and in 18 out of 21 AMD 202 
participants (9 healthy participants declined to participate and 3 AMD patients were unable to 203 
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complete either standard or low mesopic microperimetry due to unstable fixation). Out of the 204 
18 AMD patients, 15 completed both standard and low mesopic tests; however, 3 patients 205 
were able to complete only the standard test. The relationship between mean macular 206 
sensitivity and age was therefore investigated in the better eye of 18 AMD patients (standard 207 
condition), 15 AMD patients (low mesopic condition) and the dominant eye of 89 healthy 208 
participants (age 19-85 years) under standard (high mesopic) and low mesopic testing 209 
conditions (Fig. 3). There was no significant difference between grades for high mesopic 210 
microperimetry (t [13] = 0.801, p = 0.437) or low mesopic microperimetry (t [13] = 0.862, p = 211 
0.404). Within the healthy participants, there was a significant and linear decline in macular 212 
sensitivity with age for both standard (high mesopic) (F1,87 = 42.74, R2 = 0.33, p < 0.0001, 213 
slope = -0.51 % contrast per year) and low mesopic conditions (F1,87 = 125.3, R2 = 0.59, p < 214 
0.0001, slope = -0.79 % contrast per year) (Panel A, Fig. 3); a greater decline was seen under 215 
low mesopic conditions. On inclusion of the AMD patients (Panel B, Fig. 3), the slope of the 216 
regression line changed for both standard (F1,105 = 112.1, R2 = 0.52, p < 0.0001, slope = -0.73 217 
% contrast per year) and mesopic (F1,102 = 244.5, R2 = 0.71, p < 0.0001, slope = -0.99 % 218 
contrast per year) illuminations, such that it was greater compared to the loss due to normal 219 
ageing. Comparison of the AMD group and age-matched controls showed significantly lower 220 
sensitivity for the AMD group under both high mesopic (t [28] = 3.26, p = 0.003) and low 221 
mesopic (t [28] = 4.03, p < 0.0001) illumination. Analysis of the effect of eccentricity on 222 
macular sensitivity showed no significant difference between concentric rings for either of the 223 
illuminations.  Analysis of the age difference between the age-matched controls and AMD 224 
patients showed no age effect. The ROC analysis showed high sensitivity and specificity for 225 
the AMD group under both standard and mesopic test conditions (mesopic AUC = 0.96; 226 
standard AUC = 0.93). The AUC for the age-matched controls was lower than the AMD 227 
group but showed little difference between standard and mesopic conditions (mesopic AUC = 228 
0.77; standard AUC = 0.74). 229 
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 230 
We examined the risk alleles for two AMD genotypes (CFH or ARMS2) separately, as well as 231 
for the combination of both (CFH + ARMS2) in the older healthy participants (n = 24). Table 232 
2 outlines the grouping of older participants (age range 50-85 years) into high, medium or low 233 
risk alleles for the combination and single CFH and ARMS2 genotypes. Due to the small 234 
number of participants in the gene analysis, only the median and interquartile range (IQR) is 235 
reported. Pelli-Robson CS (Panel A, Fig. 4) did not differ between high, medium and low risk 236 
genotypes under photopic (median = 1.65 log CS; IQR = 0.08) or mesopic (median = 1.35 log 237 
CS; IQR = 0.15) illumination for the individual (CFH or ARMS2) or combined (CFH + 238 
ARMS2) gene variants.  MP-1 macular sensitivity (Panel B, Fig. 4) was similar between low 239 
and intermediate risk genotypes for the individual (CFH or ARMS2) and combined (CFH + 240 
ARMS2) gene variants under high mesopic (median = 86% contrast; IQR = 37) and low 241 
mesopic illumination (median = 63% contrast; IQR = 17), however, the only participant that 242 
had the highest risk with CFH (CC) and ARMS2 (GT) also showed the lowest MP-1 macular 243 
sensitivity under both the high mesopic (42 % contrast) and low mesopic illumination (54 % 244 
contrast). 245 
Insert Table 2 here. 246 
 247 
Discussion 248 
We demonstrate that mesopic Pelli-Robson contrast sensitivity detects a statistically 249 
significant reduction in contrast sensitivity in AMD that can be differentiated from normal 250 
ageing that is not differentiated under standard photopic test conditions (Fig. 1; Fig. 2). In 251 
comparison to the mesopic Pelli-Robson test; there is no further improvement in the 252 
sensitivity of the MP-1 microperimeter between the standard (high mesopic) and low mesopic 253 
test conditions (Fig. 3).  254 
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Advanced age is a main risk factor of AMD; therefore any reduction in retinal function due to 255 
normal ageing must be differentiated from that associated with AMD. While photopic VA and 256 
CS decrease gradually with age (Elliot et al. 1995; Mäntyjärvi & Laitinen 2001), less is 257 
known about mesopic vision and its relationship with age-related photopic decline in healthy 258 
participants and in patients with AMD (Feigl et al. 2011; Petzold & Plant 2006; Puell et al. 259 
2012; Puell et al. 2004). Mesopic tests that assess rods and cones under the same illumination 260 
conditions are thought to be more sensitive to early vision loss in AMD because rods are first 261 
affected (Curcio et al. 1996) and a paracrine relationship between rods and cones (Mohand-262 
Said et al. 2001) suggests that rod dysfunction consequently affects cone function. A recent 263 
study demonstrates that high contrast, low luminance VA (achieved by adding ND filters 264 
rather than by simply adjusting the illumination of the consultation room) was not more 265 
sensitive to early changes in AMD compared to high contrast, high luminance VA (Wu et al. 266 
2014). Puell et al (2012) showed that AMD patients have worse mesopic VA at both high and 267 
low contrast. Contrast sensitivity, however, is a more sensitive measure of central visual 268 
function than VA because it measures a progressive change in luminance differences between 269 
test letter and surround rather than under constant contrast conditions (Owsley 2003). The 270 
measurement of mesopic CS may therefore be more sensitive to changes in AMD than 271 
mesopic VA. Photopic CS is reduced in AMD patients compared to healthy controls using 272 
letter by letter scoring (Feigl et al. 2004), as opposed to this study where triplet scoring was 273 
used. Triplet scoring however, is recommended based on maintaining a high level of accuracy 274 
while still providing a sensitive measure of contrast (Pelli et al. 1988). A significant 275 
difference in photopic CS may have been evident had we used letter by letter scoring, 276 
however, this method can result in high susceptibility to misreporting errors (Pelli et al. 1988).  277 
MP-1 sensitivity is significantly reduced in AMD compared to age-matched healthy controls 278 
(Fig. 3); lowering the background luminance of the standard (high mesopic) microperimeter 279 
to low mesopic levels did not provide any additional advantage in detecting deficits earlier in 280 
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our study. Given that AMD deficits occur parafoveally in early stages of the disease (Cheng 281 
& Vingrys 1993; Swann & Lovie-Kitchin 1991), we conducted an analysis of the concentric 282 
rings but this did not provide additional information. Scotopic microperimetry has shown a 283 
higher sensitivity to retinal dysfunction compared with standard microperimetry in patients 284 
with drusen (Nebbioso et al. 2014), possibly due to increased sensitivity to early rod 285 
photoreceptor loss in AMD. This and our study confirm the already high sensitivity of 286 
microperimetry in detecting early stages of disease (AREDS 2 and 3) (Midena et al. 2007).  287 
We did not detect any difference in Pelli-Robson CS or MP-1 macular sensitivity between the 288 
different AMD risk genotype groups under photopic or mesopic illumination in our older 289 
healthy participants as previously detected with measurement of the mesopic CFF (Feigl et al. 290 
2011). While the application of a flickering stimulus to measure the CFF to increase the 291 
metabolic demand may be more sensitive to the presence of visual dysfunction in persons 292 
with high risk genotypes, both the CS and MP-1 tests may not provide sufficient changes to 293 
the metabolic demand required to detect the small changes in retinal function determined by a 294 
genetic predisposition. In our cohort there was only one patient with high risk gene variants 295 
for both CFH and ARMS2, and this person showed substantially decreased macular sensitivity 296 
(Fig. 4), but a larger group of patients with the combined high risk genotypes is needed to 297 
confirm this hypothesis.  298 
In conclusion, mesopic CS can be simply measured by using a readily available chart and 299 
dimming the room illumination and, together with genetic testing, may identify susceptibility 300 
to AMD. Further reduction of the illumination of standard microperimetry may allow better 301 
differentiation of deficits due to a reduced ceiling effect. Mesopic CS can detect visual loss 302 
not observed using the standard photopic CS protocol in early and intermediate AMD and 303 
may be a preferred option to microperimetry, which is more time demanding. 304 
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Figure legends 413 
Figure 1 414 
Fig. 1: Comparison of photopic and mesopic Pelli-Robson contrast sensitivity as a function of 415 
ageing and presence of early and intermediate AMD. Panel A: binocular contrast sensitivity 416 
decreases with increasing age at a similar rate under photopic (open circles) and mesopic 417 
(closed triangles) illumination (-0.004 log CS per year). Panel B: On inclusion of the AMD 418 
patients (green symbols), there is a significantly steeper decrease in contrast sensitivity when 419 
measured under mesopic illumination (-0.007 log CS per year) compared to photopic 420 
illumination (-0.004 log CS per year). 421 
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Figure 2 422 
Fig. 2: Mean (μ ± SD) monocular (better and worse eye) contrast sensitivity in AMD patients 423 
and age-matched controls shows a significant decrease in contrast sensitivity for the AMD 424 
group under mesopic illumination (closed circles) compared to photopic (open circles) 425 
illumination.  426 
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Figure 3 427 
Fig. 3: Mean (μ ± SD) macular sensitivity significantly decreases with increasing age under 428 
high mesopic (-0.51 % contrast per year; open circles) and low mesopic (-0.73 % contrast per 429 
year; closed triangles) illumination (Panel A) in healthy participants. The inclusion of the 430 
AMD patients (Panel B; green symbols) shows a greater decrease in mean macular sensitivity 431 
under both high mesopic (-0.73 % contrast per year) and low mesopic illumination (-0.99 % 432 
contrast per year).  433 
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Figure 4 434 
Fig. 4: Comparison between AMD risk genotypes in healthy older participants for photopic 435 
(open) and mesopic (pattern) Pelli-Robson CS (Panel A) and macular sensitivity (Panel B) 436 
shows no difference between high, medium and low risk genotypes. The combined high risk 437 
genotype CFH (CC) and ARMS2 (GT) is only present in one participant and shows decreased 438 
MP-1 macular sensitivity under high mesopic and low mesopic illumination (Panel B).  439 
 440 
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Tables 
Table 1: The number of AMD patients in each group classified by the study eye AREDS grade.  
AREDS Grade No. of AMD patients 
2a n = 3 
2b n = 8 
2c n = 2 
3a n = 2 
3b  n = 1 
3c n = 5 
Grade 2: n = 13 
Grade 3: n = 8 
 
 
 
Table 2: Distribution of AMD risk genotypes with risk alleles for the older age group (age 50-85 years). 
Gene variant High risk  Medium risk  Low risk  
CFH + ARMS2 
CC+TT (n = 0) 
CC+GT (n = 1) 
CT+TT (n = 0) 
CC+GG (n = 3) 
CT+GT (n = 5) 
TT+TT (n = 0) 
TT+GG (n = 4) 
CT+GG (n = 5) 
TT+GT (n = 6) 
CFH  CC (n = 4) CT (n = 10) TT (n = 10) 
ARMS2 TT (n = 0) GT (n = 12) GG (n = 12) 
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